Institutional members access full text with Ovid®

Share this article on:

Osteoporosis: Screening and Treatment in Women

POLLYCOVE, RICKI MD, MS, NCMP, FACOG*; SIMON, JAMES A. MD, CCD, NCMP, FACOG

Clinical Obstetrics and Gynecology: September 2012 - Volume 55 - Issue 3 - p 681–691
doi: 10.1097/GRF.0b013e31825caa50
Office Gynecology

Osteoporosis is frequently called the silent disease because it lacks symptoms or signs until a fracture has occurred. Osteoporosis is common in aging women because of progressive postmenopausal bone loss. Fractures related to bone loss can result in reduced quality of life, lengthy hospital stays, long-term institutionalization, and death. Early diagnosis and treatment of low bone mass to reduce fracture risk is a cost-effective element of routine health care for women. With appropriate patient screening, ObGyn care providers can implement effective interventions before fractures occur, thereby improving patients’ quality of life and reducing society’s osteoporosis-related costs.

*California Pacific Medical Center, San Francisco, California;

Department of Obstetrics and Gynecology, The George Washington University, Washington, District of Columbia

R.P. serves on the advisory boards of: Ascend Therapeutics (Herndon, VA), Azur Pharma, Inc. (Fitzwilliam Square, Dublin), Bayer HealthCare Pharmaceuticals (Wayne, NJ), NovoGyne (East Hanover, NJ), Roche Therapeutics (Nutley, NJ), GlaxoSmithKline (Research Triangle Park, NC), Shionogi Inc. (Florham Park, NJ), and previously served on the advisory board/speaker bureau for Teva Pharmaceutical Industries Ltd (Jerusalem, Israel). J.A.S. has served or is currently serving as a consultant to or on the advisory boards of: Abbott Laboratories (Abbott Park, IL), Agile Therapeutics, Inc. (Princeton, NJ), Amgen Inc. (Thousand Oaks, CA), Ascend Therapeutics (Herndon, VA), Azur Pharma, Inc. (Fitzwilliam Square, Dublin), BioSante (Lincolnshire, IL), Boehringer Ingelheim (Ingelheim, Germany), Depomed, Inc. (Menlo Park, CA), Fabre-Kramer (Houston, TX), Laboratoire HRA Pharma (Paris, France), Meditrina Pharmaceuticals (Ann Arbor, MI), Merck (Whitehouse Station, NJ), Merrion Pharmaceuticals (Wilmington, NC), NDA Partners LLC (Lakewood Ranch, FL), Novo Nordisk (Bagsvrerd, Denmark), Novogyne (East Hanover, NJ), Pfizer Inc. (New York, NY), Shionogi Inc. (Florham Park, NJ), Slate Pharmaceuticals Inc. (Durham, NC), Sprout Pharmaceuticals (Raleigh, NC), Teva Pharmaceutical Industries Ltd (Jerusalem, Israel), Trovis Pharmaceuticals, LLC (Newton, MA), Warner Chilcott (Rockaway, NJ), Watson Pharmaceutical Inc. (Corona, CA). He has received or is currently receiving grant/research support from:BioSante (Lincolnshire, IL), Boehringer Ingelheim (Ingelheim, Germany), EndoCeutics Inc. (Quebec, Quebec), Novo Nordisk (Bagsvrerd, Denmark), Novogyne (East Hanover, NJ), Palatin Technologies (Cranbury, NJ), and Teva Pharmaceutical Industries Ltd (Jerusalem, Israel), Warner Chilcott (Rockaway, NJ). He has also served or is currently serving on the speakers bureaus of: Amgen Inc. (Thousand Oaks, CA), Ascend Therapeutics (Herndon, VA), Bayer (Leverkusen, Germany), Boehringer Ingelheim (Ingelheim, Germany), Merck (Whitehouse Station, NJ), Novartis (Basel, Switzerland), Novo Nordisk (Bagsvrerd, Denmark), Novogyne (East Hanover, NJ), Teva Pharmaceutical Industries Ltd (Jerusalem, Israel), and Warner Chilcott (Rockaway, NJ).

Correspondence: Ricki Pollycove, MD, MS, NCMP, FACOG, California Pacific Medical Center, Suite 320, San Francisco, CA. E-mail: pollycove@gmail.com

© 2012 Lippincott Williams & Wilkins, Inc.